<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01276951</url>
  </required_header>
  <id_info>
    <org_study_id>Cacao III</org_study_id>
    <nct_id>NCT01276951</nct_id>
  </id_info>
  <brief_title>Controlled Clinical Trial to Determine the Effective Dose of Cocoa in Lowering Blood Pressure</brief_title>
  <official_title>Controlled Clinical Trial of the Effect of Cocoa Consumption in Lowering Blood Pressure and in the Modulation of Endothelial Inflammation in Hypertensive Patients Assigned to an Entity Health Promoting.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Antioquia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnolog√≠a (COLCIENCIAS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad de Antioquia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Colombia, ischemic heart disease and stroke are one of the most important causes of death
      in 45 years old people. Care of cases of disease represents high costs for the health system
      in particular and society in general, due to the loss of productive years life and costs for
      the care of the aftermath. Hypertension (HT) is one of the preventable risk factors for major
      cerebrovascular disorders. The pathophysiology of Essential hypertension is complex and
      depends of interaction of genetic and environmental factors. Among the determining elements
      are the increase in the activity of the sympathetic nervous system, the vasoconstricting and
      overproduction of hormones associated with sodium retention, disruption in renin secretion
      with increased production of aldosterone and angiotensin II, the deregulation of the kinins
      system, the increase in peripheral vascular resistance and activity of Growth factors in
      atherogenesis and vascular endothelial dysfunction, increased cardiac output, diabetes
      mellitus, obesity, and lower production of vasodilators such as brain natriuretic peptide
      (BNP), the prostacyclins and nitric oxide (NO), among others.

      Cocoa is a food rich in flavonoids, which stimulate the enzyme activity of endothelial nitric
      oxide synthase (e-NOS), responsible of the production of NO in vascular smooth muscle. The
      flavonoids modulate the synthesis of inflammatory substances that are derived from
      endothelial cells and the immune system.

      In a recent study found that with a few grams of cocoa achieves a significant reduction in
      blood pressure, so the investigators propose a controlled clinical trial to assess the effect
      of different doses of cocoa on blood pressure and endothelial inflammation in men with
      essential hypertension, stage I-II without target organ damage, in addition to pharmacologic
      monotherapy defined for the management of their disease. The investigators hope to determine
      an optimal dose of cocoa, with long-term effects, by their high content of flavonoids,
      improves cardiovascular and endothelial parameters with the advantage that it is an
      economical and easy introduction into the patient's habits.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change on blood pressure in patients with stage I-II hypertension, after consumption of different doses of cocoa.</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the oxidation of low density lipoproteins after cocoa consumption, in patients with stage I-II hypertension.</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the production of inflammatory molecules derived from peripheral blood mononuclear cells of patients with arterial hypertension stage I-II, after cocoa consumption.</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in platelet aggregation after cocoa consumption, in patients with essential arterial hypertension stage I-II.</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6,5g Dose Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>12g Dose Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>25g Dose Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>50g Dose Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Delivery and return of chocolate</intervention_name>
    <description>At baseline and then every 2 weeks, each participant will receive different grams of chocolate, according to the group to which he is assigned.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>6,5g Dose Group</arm_group_label>
    <arm_group_label>12g Dose Group</arm_group_label>
    <arm_group_label>25g Dose Group</arm_group_label>
    <arm_group_label>50g Dose Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Determination of blood pressure</intervention_name>
    <description>Blood pressure will be determined at study entry, ninth and eighteenth week taking into account the protocols established in 2007 by the European Society of Cardiology and Hypertension. Because blood pressure has variations throughout the day and that measuring ambulatory health institutions can generate emotional changes that induce changes in this clinical setting, which for purposes of this study is the main outcome variable, there will be 24-hour monitoring of blood pressure at the beginning and end of the study.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>6,5g Dose Group</arm_group_label>
    <arm_group_label>12g Dose Group</arm_group_label>
    <arm_group_label>25g Dose Group</arm_group_label>
    <arm_group_label>50g Dose Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Anthropometric Measurements</intervention_name>
    <description>The study will be determined the body mass index (BMI) by the ratio of weight in kilograms over height in meters squared, for which anthropometric measurement will be made at first, ninth and the eighteenth week as follows: The weight will be taken with an electronic balance of 0.05 g sensitivity standing capacity of 150 kg. We will be rated based on BMI cut points given by WHO-PAHO (1993) and adopted by the Ministry of Health of Colombia (2000).</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>6,5g Dose Group</arm_group_label>
    <arm_group_label>12g Dose Group</arm_group_label>
    <arm_group_label>25g Dose Group</arm_group_label>
    <arm_group_label>50g Dose Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Food Anamnesis</intervention_name>
    <description>With the aim of learning about the eating habits, it will be made based on a food intake recall the last 24 hours, taking into account that is not preceded by a special food day (sundays, holidays, celebrations). For more accurately calculate nutrient ingested food, modules will be used.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>6,5g Dose Group</arm_group_label>
    <arm_group_label>12g Dose Group</arm_group_label>
    <arm_group_label>25g Dose Group</arm_group_label>
    <arm_group_label>50g Dose Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Samples: serological tests and culture of mononuclear cells</intervention_name>
    <description>At admission and at the end of the study will be obtained after 12 hours of fasting, 8 mL of blood in a dry tube without anticoagulant and 30 mL of blood in heparin tubes, properly labeled with the code assigned to the participant. The sample will be used to determine the complete lipid profile (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol and VLDL cholesterol), State of oxidation of low density lipoprotein (oxLDL) and mononuclear cell culture. The remaining serum was kept at -20¬∞C for use if is required repeat any study.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>6,5g Dose Group</arm_group_label>
    <arm_group_label>12g Dose Group</arm_group_label>
    <arm_group_label>25g Dose Group</arm_group_label>
    <arm_group_label>50g Dose Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Analysis of cytokine production</intervention_name>
    <description>We will be used the supernatant of mononuclears cell culture to quantify the production of interleukin one beta, interleukin two, tumor necrosis factor alpha by ELISA with commercially available kits for this purpose.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>6,5g Dose Group</arm_group_label>
    <arm_group_label>12g Dose Group</arm_group_label>
    <arm_group_label>25g Dose Group</arm_group_label>
    <arm_group_label>50g Dose Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Age: 18 - 65 years old

          -  Resides in Medell√≠n City

          -  Attached from the contributive regimen of Colombian Health System

          -  Essential Arterial Hypertension, stage I or II.

          -  Be receiving pharmacologic therapy (maximum 2 medications), whose dose has been stable
             for eight weeks prior to study entry.

          -  Voluntary desire to consume 6,5; 12; 25 or 50 grams of chocolate per day for 18 weeks.

          -  Voluntary desire to participate in the trial and sign informed consent.

        Exclusion Criteria:

          -  Secondary hypertension

          -  Injury in target organ: heart, kidney, brain and retina

          -  Presence of diabetes mellitus

          -  BMI (Body Mass Index) major or equal to 30

          -  Present smoker or with less than four weeks of abstinence of tobacco

          -  Consume antiplatelet substances

          -  Regular consumption of antioxidants and multivitamins

          -  During the study excluded any participant to present a sudden increase in blood
             pressure: SBP greater than or equal to 180 mmHg and/or DBP greater or equal to 110 mm
             Hg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M√≥nica L. Giraldo Restrepo, Nurse. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sede Investigaciones Universitarias, Universidad de Antioquia</name>
      <address>
        <city>Medell√≠n</city>
        <state>Antioquia</state>
        <zip>05001000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <reference>
    <citation>Grassi D, Necozione S, Lippi C, Croce G, Valeri L, Pasqualetti P, Desideri G, Blumberg JB, Ferri C. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension. 2005 Aug;46(2):398-405. Epub 2005 Jul 18.</citation>
    <PMID>16027246</PMID>
  </reference>
  <reference>
    <citation>WHO publishes definitive atlas on global heart disease and stroke epidemic. Indian J Med Sci. 2004 Sep;58(9):405-6.</citation>
    <PMID>15902773</PMID>
  </reference>
  <reference>
    <citation>Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003 Nov 4;139(9):761-76. Review.</citation>
    <PMID>14597461</PMID>
  </reference>
  <reference>
    <citation>C√≠fkov√° R. The burden of hypertension and inadequate control in populations. J Hypertens. 2006 May;24(5):807-9.</citation>
    <PMID>16612237</PMID>
  </reference>
  <reference>
    <citation>Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec;42(6):1206-52. Epub 2003 Dec 1.</citation>
    <PMID>14656957</PMID>
  </reference>
  <reference>
    <citation>Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004 Jan;22(1):11-9. Review.</citation>
    <PMID>15106785</PMID>
  </reference>
  <reference>
    <citation>Aristizabal D GE, McEwen J, Caulfiel M, Mendez J, Medina E, Zapata N, Correa M. Bases gen√©ticas de la hipertension arterial esencial en Colombia: avances en nueve a√±os de estudio. Revista Colombiana de Cardiolog√≠a. 12(6), 2006.</citation>
  </reference>
  <reference>
    <citation>Beevers G, Lip GY, O'Brien E. ABC of hypertension: The pathophysiology of hypertension. BMJ. 2001 Apr 14;322(7291):912-6. Review.</citation>
    <PMID>11302910</PMID>
  </reference>
  <reference>
    <citation>Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007 Jun;25(6):1105-87. Erratum in: J Hypertens. 2007 Aug;25(8):1749.</citation>
    <PMID>17563527</PMID>
  </reference>
  <reference>
    <citation>Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002 Nov;8(11):1211-7.</citation>
    <PMID>12411947</PMID>
  </reference>
  <reference>
    <citation>Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-72. Epub 2003 May 14. Erratum in: JAMA. 2003 Jul 9;290(2):197.</citation>
    <PMID>12748199</PMID>
  </reference>
  <reference>
    <citation>Taubert D, Roesen R, Sch√∂mig E. Effect of cocoa and tea intake on blood pressure: a meta-analysis. Arch Intern Med. 2007 Apr 9;167(7):626-34.</citation>
    <PMID>17420419</PMID>
  </reference>
  <reference>
    <citation>Schroeter H, Heiss C, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, Sies H, Kwik-Uribe C, Schmitz HH, Kelm M. (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1024-9. Epub 2006 Jan 17.</citation>
    <PMID>16418281</PMID>
  </reference>
  <reference>
    <citation>McCullough ML, Chevaux K, Jackson L, Preston M, Martinez G, Schmitz HH, Coletti C, Campos H, Hollenberg NK. Hypertension, the Kuna, and the epidemiology of flavanols. J Cardiovasc Pharmacol. 2006;47 Suppl 2:S103-9; discussion 119-21.</citation>
    <PMID>16794446</PMID>
  </reference>
  <reference>
    <citation>Fisher ND, Sorond FA, Hollenberg NK. Cocoa flavanols and brain perfusion. J Cardiovasc Pharmacol. 2006;47 Suppl 2:S210-4.</citation>
    <PMID>16794460</PMID>
  </reference>
  <reference>
    <citation>Tsuruchi N, Jimi S. [A case of recurrent endometrial cancer successfully treated with oral administration of etoposide]. Gan To Kagaku Ryoho. 1992 Jan;19(1):103-5. Japanese.</citation>
    <PMID>1729957</PMID>
  </reference>
  <reference>
    <citation>Farouque HM, Leung M, Hope SA, Baldi M, Schechter C, Cameron JD, Meredith IT. Acute and chronic effects of flavanol-rich cocoa on vascular function in subjects with coronary artery disease: a randomized double-blind placebo-controlled study. Clin Sci (Lond). 2006 Jul;111(1):71-80.</citation>
    <PMID>16551272</PMID>
  </reference>
  <reference>
    <citation>Taubert D, Roesen R, Lehmann C, Jung N, Sch√∂mig E. Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide: a randomized controlled trial. JAMA. 2007 Jul 4;298(1):49-60.</citation>
    <PMID>17609490</PMID>
  </reference>
  <reference>
    <citation>Taubert D, Berkels R, Roesen R, Klaus W. Chocolate and blood pressure in elderly individuals with isolated systolic hypertension. JAMA. 2003 Aug 27;290(8):1029-30.</citation>
    <PMID>12941673</PMID>
  </reference>
  <reference>
    <citation>Grassi D, Lippi C, Necozione S, Desideri G, Ferri C. Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am J Clin Nutr. 2005 Mar;81(3):611-4.</citation>
    <PMID>15755830</PMID>
  </reference>
  <reference>
    <citation>Heiss C, Dejam A, Kleinbongard P, Schewe T, Sies H, Kelm M. Vascular effects of cocoa rich in flavan-3-ols. JAMA. 2003 Aug 27;290(8):1030-1.</citation>
    <PMID>12941674</PMID>
  </reference>
  <reference>
    <citation>Mursu J, Voutilainen S, Nurmi T, Rissanen TH, Virtanen JK, Kaikkonen J, Nyyss√∂nen K, Salonen JT. Dark chocolate consumption increases HDL cholesterol concentration and chocolate fatty acids may inhibit lipid peroxidation in healthy humans. Free Radic Biol Med. 2004 Nov 1;37(9):1351-9.</citation>
    <PMID>15454274</PMID>
  </reference>
  <reference>
    <citation>Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, Witztum JL. Innate and acquired immunity in atherogenesis. Nat Med. 2002 Nov;8(11):1218-26. Review.</citation>
    <PMID>12411948</PMID>
  </reference>
  <reference>
    <citation>Selmi C, Mao TK, Keen CL, Schmitz HH, Eric Gershwin M. The anti-inflammatory properties of cocoa flavanols. J Cardiovasc Pharmacol. 2006;47 Suppl 2:S163-71; discussion S172-6. Review.</citation>
    <PMID>16794453</PMID>
  </reference>
  <reference>
    <citation>Keen CL, Holt RR, Oteiza PI, Fraga CG, Schmitz HH. Cocoa antioxidants and cardiovascular health. Am J Clin Nutr. 2005 Jan;81(1 Suppl):298S-303S. doi: 10.1093/ajcn/81.1.298S. Review.</citation>
    <PMID>15640494</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2011</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cocoa</keyword>
  <keyword>Chocolate</keyword>
  <keyword>Endothelial disfunction</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

